ACAD Stock Summary and Trading Ideas (Acadia Pharmaceuticals | NASDAQ:ACAD)

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.

As of April 16, 2024, ACAD stock price climbed to $17.08 with 919,001 million shares trading.

ACAD has a beta of 1.69, meaning it tends to be more sensitive to market movements. ACAD has a correlation of 0.10 to the broad based SPY ETF.

ACAD has a market cap of $2.73 billion. This is considered a Mid Cap stock.

Last quarter Acadia Pharmaceuticals reported $231 million in Revenue and $.28 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.02.

In the last 3 years, ACAD stock traded as high as $33.99 and as low as $12.24.

The top ETF exchange traded funds that ACAD belongs to (by Net Assets): VTI, VB, XBI, IWM, VXF.

ACAD has underperformed the market in the last year with a price return of -5.1% while the SPY ETF gained +23.7%. ACAD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.5% and -6.5%, respectively, while the SPY returned +6.0% and -3.6%, respectively.

ACAD support price is $16.56 and resistance is $17.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD stock will trade within this expected range on the day.